Camp4 Therapeutics (CAMP) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary

Platform overview and differentiation

• RAP Platform uses antisense oligonucleotides to target regulatory RNAs, enabling upregulation of gene expression in diseases with protein deficiencies.

• Proprietary database catalogs thousands of regulatory RNAs across tissues, leveraging next-gen sequencing and machine learning for rapid target identification.

• Platform focuses on established oligonucleotide chemistry, reducing risk and accelerating clinical translation.

• Approach enables targeting both rare and prevalent diseases, with initial focus on high unmet need genetic disorders.

• Business development and partnerships are integral, with recent deals expanding platform reach beyond internal pipeline.

Pipeline progress and clinical updates

• Lead asset CMP-CPS-001 is in phase one for urea cycle disorders; SAD portion showed favorable safety, MAD data expected in H2 2025.

• SYNGAP1 program targets genetic epilepsy; IND-enabling studies planned for later this year, aiming for clinical entry.

• New CNS program initiated for GBA1 mutation in Parkinson's, with potential to expand into idiopathic Parkinson's population.

• Biomarker-driven approach in clinical trials uses sodium acetate clearance to assess urea cycle function.

• Orphan drug and rare pediatric designations secured, supporting efficient regulatory pathways.

Market opportunity and strategy

• Urea cycle disorder market estimated at 4,000 severe patients in the U.S., plus 1,000–1,500 symptomatic female carriers.

• Current treatments are not disease-modifying and impose significant lifestyle burdens; high unmet need supports strong pricing potential.

• RNA-based therapies in ultra-rare diseases can command premium pricing, with Ravicti cited at $750,000–$850,000 per year.

• Platform's broad applicability allows for expansion into larger indications and supports active business development.

• Focus on diseases with strong genetic validation and clear potential for disease modification.